mRNA driven drugs and vaccines maker Stemirna Therapeutics on Thursday announced that it has raked in 1.2 billion yuan ($188 million) in a new funding round jointly led by Sequoia Capital China, state-backed China Merchants Medical and Healthcare Industry Equity Fund, Chinese global pharma major WuXi AppTec and Greenwoods Investment.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
